GlycoVaxyn develops novel conjugated vaccines targeting diarrheal disease and other bacterial infections and currently has various products in the preclinical development. The company has identified opportunities to prevent bacterial infectious disease in the industrialized and emerging world using conjugated vaccines produced by its technology. The business model is based on the expectation to license out vaccine product to major vaccine companies at the late clinical stage. The most advanced product will enter clinical tests in 2009.
GlycoVaxyn has developed a proprietary technology that allows the production of glycoproteins in simple prokaryotic cells. A variety of conjugated vaccines, e.g. combinations of sugar antigens of bacterial origin with protein carriers are produced. Expression strains for combinations of different sugar antigen-protein carrier conjugates are available. The technology offers various advantages: 1) Production of novel conjugated vaccines 2) More homogenous glycosylation pattern 3) Lowering of production costs 4) Increase of speed of development 5) Entering emerging world.

Speaker Profile

Urs Tuor

Urs Tuor graduated as an organic chemist at the University of Zürich and elucidated wood degradation mechanisms by fungi during his Ph.D. at the Institute of Biotechnology of the ETH in Zürich. His next research assignment took him to the biological control of insect agricultural pests using fungal pathogens. His professional experience covers the environmental industry as a consultant and engineering work relating to decontamination of polluted industrial sites. His last assignment was with the Swiss private bank Sarasin, covering the chemical sector as a sell-side analyst. Since beginning of 2005, he is in charge of GlycoVaxyn’s corporate development.